|
Jan 13
|
Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?
|
|
Jan 9
|
Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?
|
|
Jan 8
|
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
|
|
Jan 1
|
Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate
|
|
Sep 26
|
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
|
|
Jun 10
|
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
|
|
May 13
|
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
|
|
Apr 24
|
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
|
|
Apr 23
|
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
|
|
Apr 22
|
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
|
|
Mar 28
|
Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results
|
|
Mar 28
|
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
|
|
Mar 27
|
Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares
|
|
Mar 12
|
Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m
|
|
Feb 22
|
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
|
|
Dec 27
|
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
|
|
Dec 26
|
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
|
|
Dec 10
|
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
|
|
Dec 5
|
Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect?
|
|
Nov 27
|
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
|